None listed
Conditions
Brief summary
This study is a 16 week, double blind, placebo controlled investigation of the effects of a Women’s 50+ multivitamin antioxidant supplement on memory and brain function in women aged 65 to 80 years who are experiencing memory decline. Additionally, this study aims to investigate the possible mechanisms which underlie memory impairment in older adults including cardiovascular risk factors, oxidative stress and brain activity (EEG).
Interventions
Swisse Women's Ulitivite 50+ V One tablet per day for 16 weeks. RETINYL ACETATE (equiv. to 2500 IU of vitamin A) 862.5 mcg d-ALPHA-TOCOPHERYL ACID SUCCINATE (equiv. vitamin E 24.2 IU) 20 mg THIAMINE HYDROCHLORIDE (vitamin B1) 30 mg RIBOFLAVINE (vitamin B2) 30 mg NICOTINAMIDE (vitamin B3) 20 mg CALCIUM PANTOTHENATE (vitamin B5) (equiv. pantothenic acid 64.13mg) 70 mg PYRIDOXINE HYDROCHLORIDE (vitamin B6) (equiv. pyridoxine 24.68mg) 30 mg CYANOCOBALAMIN (vitamin B12) 115 mcg CHOLECALCIFEROL (vitamin D3) (equiv. vitamin D 200 IU) 5mcg BIOTIN (vitamin H) 150 mcg FOLIC ACID 500 mcg CALCIUM ASCORBATE DIHYDRATE (vitamin C)(equiv. ascorbic acid 165.3mg) 200 mg PHYTOMENADIONE (vitamin K1) 60 mcg CITRUS BIOFLAVONOIDS EXTRACT 20 mg CALCIUM OROTATE (equiv. calcium 10mg) 100 mg MAGNESIUM ASPARTATE DIHYDRATE (equiv. magnesium 6.74mg) 100 mg SELENOMETHIONINE (equiv. selenium 26mcg) 65 mcg MOLYBDENUM TRIOXIDE (equiv. molybdenum 45mcg) 67.5 mcg CHROMIUM PICOLINATE (equiv. chromium 50 mcg) 402 mcg MANGANESE AMINO ACID CHELATE (equiv. manganese 3mg) 30 mg FERROUS FUMERATE (equiv. iron 5mg) 16.01 mg COPPER GLUCONATE (equiv. copper 1.2mg) 8.57 mg POTASSIUM IODIDE (equiv. iodine 149.83mcg) (equiv. potassium 46.18mcg) 196 mcg ZINC AMINO ACID CHELATE (equiv. zinc 15mg) 75 mg Lactobacillius rhamnosus 80 million organisms Lactobacillus acidophilus 80 million organisms Bifidobacterium longum 35 million organisms VACCINIUM MACROCARPON FRUIT DRY (patented cranberry PACRAN) 800 mg SILYBUM MARIANUM DRY FRUIT (St. Mary’s thistle) (equiv. flavanolignans calculated as silybin 17.14mg) 1500 mg GINKGO BILOBA LEAF DRY (Maidenhair tree) (equiv. Ginkgo flavonglycosides 4.8mg and ginkgolides and bilobalide 1.2mg) 1000 mg TUNERA DIFFUSA LEAF DRY (Damiana) 500 mg SCUTELLARIA LATERIFLORA HERB DRY (Skullcap) 50 mg VITIS VINIFERA DRY SEED (Grape seed) (equiv. procyanidins 7.9mg) 1000 mg URTICA DIOICA LEAF DRY (Nettle) 100 mg UBIDECARENONE (Co-enzyme Q10) (from patented Ultrasome CoQ10) 2 mg CYNARA SCOLYMUS LEAF DRY (Globe artichoke) 50 mg CIMICIFUGA RACEMOSA ROOT & RHIZOME DRY (Black cohosh) 200 mg CURCUMA LONGA RHIZOME DRY (Tumeric) 100 mg WITHANIA SOMNIFERA ROOT DRY (Ashwagandha) 500 mg CRATAEGUS MONOGYNA FRUIT DRY (Hawthorn) 100 mg SILICA COLLOIDAL ANHYDROUS (equiv. silicon 9.35mg) 20 mg BACOPA MONNIERI WHOLE PLANT DRY (Bacopa) (equiv. bacosides calculated as bacoside A 1.125mg) 50 mg LECITHIN POWDER – SOY PHOSPHATIDYLSERINE ENRICHED SOY (equiv. phosphatidylserine 2mg) 10 mg SPEARMINT OIL 2 mg VACCINIUM MYRTILLUS FRUIT DRY (Bilberry) (equiv. anthocyanosides 324mcg) 100 mg TAGETES ERECTA FLOWER DRY (Marigold) (Lutein esters calculated as lutein (of Tagetes erecta) 1mg) 100 mg
Sponsors
Dr Andrew Pipingas
Study design
Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used)
Eligibility
Sex/Gender
All
Age
65 Years to 80 Years
Healthy volunteers
Yes
Inclusion criteria
Females aged 65- 80 years who are experiencing memory decline.
Exclusion criteria
Smoking; current supplementation with multivitamins; history of psychiatric disorder, neurological disease, dementia.
Outcome results
None listed